Levofloxacin-induced dyskinesia in an elderly patient with granulomatosis with polyangiitis
Abstract
This case report presents an early 60s male patient who developed generalised tremor and dyskinesia within 24 hours of initiating levofloxacin treatment for community-acquired pneumonia and was diagnosed with granulomatous polyangiitis. The patient was receiving immunosuppressive therapy with rituximab and corticosteroids. Neurological examination revealed choreiform movements and gait disturbance, but laboratory parameters, including brain imaging and kidney and liver function tests, were normal. Alternative causes, such as infections, metabolic imbalances and neurodegenerative conditions were ruled out. After levofloxacin was discontinued, the patient's symptoms improved rapidly, and complete recovery was observed within 1 week. A literature review revealed that the number of similar cases is limited. This case demonstrates that levofloxacin-induced movement disorders, although rare, may occur, particularly in elderly patients or those with underlying comorbidities. Proposed mechanisms include GABA-A receptor inhibition and NMDA receptor activation, which contribute to neuronal hyperexcitability. This case highlights the importance of recognising fluoroquinolone-induced neurotoxicity as a potential side effect, particularly in susceptible populations.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Neuroprotective Effects of Epicatechin against Oxidative Stress-Induced Cognitive Impairment: A Systematic Review and Meta-Analysis
- Photochemical behavior of levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.